Citations

Clear

439 citation(s) found for "Stone, M".

Poster 344: The New "Terrible Triad": Anterior Cruciate Ligament Reconstruction With Concurrent Meniscal Lateral Root and Medial Ramp Repairs
Shoemaker, Evan P , Tollefson, Luke V. , Kennedy, Nicholas I. , Homan, Morgan D. , Shah, Ayush , Sieffert, Kayla J., Wulf, Corey A., Bjerke, Brian, McGaver, Rebecca Stone , Larson, Christopher Michael , LaPrade, Robert F.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00310 Get It

Objectives: The purpose of this paper was to compare patient reported outcomes (PROMs) between isolated anterior cruciate ligament (ACLR) and ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs and compare PROMs between different medial meniscus ramp and lateral meniscus root repair techniques. Methods: All patients with isolated (ISO) ACL reconstruction or ACL reconstruction with concomitant medial meniscus ramp and lateral meniscus root repairs with a minimum 2 years of follow-up were retrospectively evaluated. Institutional review board approval was obtained for this study. A final total of 42 ISO-ACL patients were matched based upon age, sex, and body mass index to 40 in the “terrible triad” (TT) cohorts. Outcome measures were obtained from 32 patients in the ISO cohort, and 38 patients in the TT cohort. The PROMs used for this study include the International Knee Documentation Committee (IKDC) Subjective Knee, Cincinnati, Tegner, Lysholm, Veterans RAND 12-Item Health Survey (VR-12), and Knee Injury and Osteoarthritis Outcomes Score (KOOS) questionnaire forms. T tests and chi-square goodness of fit tests were used to compare the above PROMs both pre- and postoperatively within each cohort, and between cohorts and rates of revision or reoperation. Results: The preoperative and postoperative PROMs between patients in the isolated cohort and the triad cohort demonstrated no significant differences, except for the Physical category of the VR-12, in which the triad cohort had significantly higher results (p = 0.04) (Figure 1). Both the isolated cohort and the triad cohort reported significant differences between pre- and postoperative PROMs within their own cohorts. When comparing methods of surgery, including all-inside vs. inside-out for the medial meniscus repairs and tunnel versus no-tunnel for the lateral meniscus root repairs, no significant differences were found between postoperative PROMs. Additionally, no significant difference was found in revision or reoperative rates between the triad and isolated cohorts (p = 0.374) (Figure 2), the all-inside versus inside-out medial meniscus cohorts (p = 0.267), or the tunnel vs. no-tunnel lateral meniscus cohorts (p = 0.781). Conclusions: There was no significant difference in PROMs between isolated ACLR versus ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs. While the complexity of the TT ACLR patients was more involved, PROMs and healing rates were similar and performing concurrent medial ramp and lateral root repairs at the time of ACLR should be considered.
The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria
Breeggemann, Matthew C. , Wood, Kyle D. , Harris, Peter C. , Lieske, John C. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | August 2, 2024 | Volume: 212 | Issue: 5 | Pages: 649-659

10.1097/ju.0000000000004147 | PMID 39093847 Get It

ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).
Hamilton, Ashley, Kelley, Robin Kate , Al-Rajabi, Raed Moh’d Taiseer , Gutierrez, Martin , Fonkoua, Lionel Aurelien Kankeu , Kardosh, Adel, Bondanza, Attilio , Stone, John , Li, Daneng , Melero, Ignacio , Abou‐Alfa, Ghassan K. , Alese, Olatunji B. , Babiker, Hani M. , Borad, Mitesh J. , Dayyani, Farshid , Hong, Jung Yong , Karasic, Thomas Benjamin , Keenan, Bridget P. , Noonan, Anne M. , Saeed, Anwaar

Mayo Clinic

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS2675-TPS2675

10.1200/jco.2024.42.16_suppl.tps2675 Get It

TPS2675 Background: Checkpoint inhibitor therapy is the standard first-line treatment for advanced/recurrent HCC, but there is a significant unmet therapeutic need for patients (pts) who progress after first-line treatment. Adoptive cellular immunotherapy may provide a novel treatment option. Glypican-3 (GPC3), a heparan sulfate proteoglycan, is overexpressed by tumor cells in HCC and virtually absent in healthy tissues, making it an ideal target for CAR-T therapy. AZD5851 is an autologous CAR-T product that expresses a CAR specific for GPC3 and a dominant negative (dn)TGFβRII as an armoring strategy. Expression of dnTGFβRII can block TGFβ signaling, protecting CAR T-cells from the immunosuppressive effects of this cytokine. Early clinical data with C-CAR031, a CAR-T product with the same GPC3-specific CAR and dnTGFβRII-armoring transgene as AZD5851, showed promising tolerability and antitumor activity in pts with HCC [1]. ATHENA (NCT06084884) is a first-in-human, single-arm, open-label, multicenter phase 1/2 study to evaluate the safety, tolerability, and antitumor activity of AZD5851 in pts with GPC3+ advanced/recurrent HCC, for whom ≥1 prior line of standard therapy failed or was not tolerable. Methods: Eligible pts are aged ≥18 years with histologically confirmed advanced/recurrent or metastatic and/or unresectable HCC, GPC3+ tumor sample as determined by immunohistochemistry, ≥1 prior line of standard systemic therapy, ≥1 measurable lesion per RECIST 1.1, Child-Pugh A, ECOG PS 0/1, and adequate organ and bone marrow function. Approximately 24 pts will be enrolled in Part A (Phase I, dose escalation) and 50 in Part B (Phase II dose expansion). Pts will undergo apheresis to collect peripheral blood mononuclear cells for AZD5851 production, after which they may receive approved bridging therapy for disease control. Upon successful generation of AZD5851 product, pts will undergo lymphodepletion before receiving a single dose of IV AZD5851. Subsequent follow-up is divided into 3 stages: Stage 1, active follow-up of all pts through 6 months post AZD5851 infusion; Stage 2, further evaluation of pts who have not progressed or started a new anticancer regimen during Stage 1; Stage 3, long-term follow-up for all pts who have received AZD5851. The primary endpoints are to assess the safety/tolerability of AZD5851 (both study parts), and to determine the recommended dose(s) of AZD5851 for expansion and phase 2 trials (Part A). Secondary endpoints include efficacy (objective response rate, best overall response, duration of response, disease control rate, durable response rate, time to response, progression-free survival, and overall survival) and pharmacokinetics. Exploratory endpoints include pharmacodynamic biomarkers and immunogenicity. Enrollment began Nov 2023. 1. Zhang et al. AACR 2023. Abstract CT097. Clinical trial information: NCT06084884 .
Global Trends in Kidney Stone Awareness: A Time Series Analysis from 2004–2023
Aiumtrakul, Noppawit , Suppadungsuk, Supawadee , Krisanapan, Pajaree , Pinthusopon, Preyarat, Mao, Michael A. , Arayangkool, Chinnawat , Vo, Kristine B. , Wannaphut, Chalothorn , Miao, Jing , Cheungpasitporn, Wisit , Suppadungsuk, Supawadee , Krisanapan, Pajaree , Mao, Michael A , Arayangkool, Chinnawat , Vo, Kristine B , Miao, Jing , Cheungpasitporn, Wisit , Aiumtrakul, Noppawit , Wannaphut, Chalothorn , Thongprayoon, Charat

Mayo Clinic

Clinics and Practice | May 21, 2024 | Volume: 14 | Issue: 3 | Pages: 915-927

10.3390/clinpract14030072 | PMID 38804404 Get It

Background: Despite the prevalence and incidence of kidney stones progressively increasing worldwide, public awareness of this condition remains unclear. Understanding trends of awareness can assist healthcare professionals and policymakers in planning and implementing targeted health interventions. This study investigated online search interest in “kidney stone” by analyzing Google Trends, focusing on stationarity of the trends and predicting future trends. Methods: We performed time series analysis on worldwide Google monthly search data from January 2004 to November 2023. The Augmented Dickey–Fuller (ADF) test was used to assess the stationarity of the data, with a p-value below 0.05 indicating stationarity. Time series forecasting was performed using the autoregressive integrated moving average to predict future trends. Results: The highest search interest for “kidney stone” (score 100) was in August 2022, while the lowest was in December 2007 (score 36). As of November 2023, search interest remained high, at 92. The ADF test was significant (p = 0.023), confirming data stationarity. The time series forecasting projected continued high public interest, likely reflecting ongoing concern and awareness. Notably, diverse regions such as Iran, the Philippines, Ecuador, the United States, and Nepal showed significant interest, suggesting widespread awareness of nephrolithiasis. Conclusion: This study highlighted that “kidney stone” is a consistently relevant health issue globally. The increase and stationarity of search trends, the forecasted sustained interest, and diverse regional interest emphasize the need for collaborative research and educational initiatives. This study’s analysis serves as a valuable tool for shaping future healthcare policies and research directions in addressing nephrolithiasis related health challenges.
A Canine Model Implicates Uromodulin Peptides in Calcium Oxalate Urinary Stone Risk
Wesson, Jeffrey A. , Jayachandran, Muthuvel, Furrow, Eva , Rampoldi, Luca , Jovine, Luca , Jayachandran, Muthuvel , Lieske, John C. , Romero, Michael F. , Lulıch, Jody P.

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 568-568

10.1681/asn.20233411s1568c Get It

Risk of Symptomatic Kidney Stones After Kidney Donor Evaluation in Stone Formers
Keddis, Mira T. , Quillen, Jaxon , Khamash, Hasan , Porter, Ivan E. , Zhang, Nan , D’Costa, Matthew R. , Jadlowiec, Caroline C. , Wadei, Hani M. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 343-343

10.1681/asn.20233411s1343b Get It

Systemic Inflammation and Kidney Stone Disease in Autosomal Dominant Polycystic Kidney Disease
You, Zhiying , Brosnahan, Godela , Chapman, Arlene B., Chonchol, Michel , Gitomer, Berenice Y , Wang, Wei , Hopp, Katharina , Nowak, Kristen L. , Perrone, Ronald D. , Torres, Vicente E. , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 159-159

10.1681/asn.20223311s1159b Get It

Antibiotic Use and Kidney Stone Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
You, Zhiying , Brosnahan, Godela , Jovanovich, Anna, Chapman, Arlene B., Chonchol, Michel , Gitomer, Berenice Y , Wang, Wei , Hopp, Katharina , Nowak, Kristen L. , Jovanovich, Anna J. , Perrone, Ronald D. , Torres, Vicente E. , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 159-159

10.1681/asn.20223311s1159a Get It

12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1
Saland, Jeffrey M. , Groothoff, Jaap W. , Frishberg, Yaacov, Hulton, Sally A., Koren, Michael J. , Overcash, Jeffrey S., Sellier-Leclerc, Anne-Laure A., Shasha‐Lavsky, Hadas , Magen, Daniella , Moochhala, Shabbir H. , Šimková, Eva, Sas, David J. , Meliambro, Kristin, Ngo, Taylor , Fujita, Kenji P. , Gansner, John M. , McGregor, Tracy L., Sellier‐Leclerc, Anne‐Laure , Deschênes, Georges , Hayes, Wesley Nathan , Fuster, Daniel Guido , Coenen, Martin , Garrelfs, Sander F. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: B8-B8

10.1681/asn.20203110s1b8c Get It